Want to see NUWE full AI Analyst Report?
NUWE Stock Chart & Stats
$2.05
-$0.15(-6.82%)
At close: 4:00 PM EDT
$2.05
-$0.15(-6.82%)
Day’s Range― - ―
52-Week Range$1.61 - $336.00
Previous CloseN/A
Volume154.60K
Average Volume (3M)289.18K
Market Cap
$633.87K
Enterprise Value$0.37
Total Cash (Recent Filing)$2.08M
Total Debt (Recent Filing)$265.00K
Price to Earnings (P/E)―
Beta2.18
Next Earnings
Aug 13, 2026EPS Estimate
-23.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2240.70
Shares Outstanding364,295
10 Day Avg. Volume82,161
30 Day Avg. Volume289,177
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)4.58
Price to Sales (P/S)1.45
P/FCF Ratio-1.10
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-80.15
Revenue Forecast (FY)$9.87M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables AnnuityThe business generates recurring revenue from single-use disposables tied to each treatment, creating an annuity stream as installed systems are used. Durable demand for consumables supports predictable cashflows per procedure and scales with installed base and utilization over months to years.
High Gross MarginsSustained gross margins near 70% indicate the core product and consumable economics are favorable. With improved pricing, mix and contract manufacturing, margin sustainability supports reinvestment in sales and clinical adoption and underpins leverage as revenue scales over the next 2–6 months.
Pediatric Commercial TractionRapid pediatric adoption and placements at leading children’s hospitals validate a focused growth vertical with higher procedure concentration. A robust pediatric installed base can drive recurring circuit sales, referenceability, and durable clinical adoption that supports long-term revenue expansion.
Bears Say
High Cash BurnMulti-year negative operating and free cash flow indicate the company continues to consume capital faster than it generates it. Unless revenue scales meaningfully or burn is cut per management targets, ongoing outflows create structural financing risk over the coming quarters.
Operating Losses Exceed RevenueExpenses remain far ahead of current sales, producing deeply negative operating and net margins. This structural unprofitability means the company must either materially scale revenue or sustain sharp cost reductions to achieve durable profitability within a 2–6 month horizon.
Limited LiquidityModest cash on hand relative to quarterly operating losses leaves a narrow runway and reliance on capital markets or dilutive financings. This structural liquidity constraint increases execution risk for commercialization and product rollout plans absent rapid burn reduction or new funding.
Nuwellis News
NUWE FAQ
What was Nuwellis’s price range in the past 12 months?
Nuwellis lowest stock price was $1.61 and its highest was $336.00 in the past 12 months.
What is Nuwellis’s market cap?
Nuwellis’s market cap is $633.87K.
When is Nuwellis’s upcoming earnings report date?
Nuwellis’s upcoming earnings report date is Aug 13, 2026 which is in 10 days.
How were Nuwellis’s earnings last quarter?
Nuwellis released its earnings results on May 12, 2026. The company reported -$73.15 earnings per share for the quarter, missing the consensus estimate of -$35 by -$38.15.
Is Nuwellis overvalued?
According to Wall Street analysts Nuwellis’s price is currently Overvalued.
Does Nuwellis pay dividends?
Nuwellis does not currently pay dividends.
What is Nuwellis’s EPS estimate?
Nuwellis’s EPS estimate is -23.8.
How many shares outstanding does Nuwellis have?
Nuwellis has 364,295 shares outstanding.
What happened to Nuwellis’s price movement after its last earnings report?
Nuwellis reported an EPS of -$73.15 in its last earnings report, missing expectations of -$35. Following the earnings report the stock price went down -0.959%.
Which hedge fund is a major shareholder of Nuwellis?
Currently, no hedge funds are holding shares in NUWE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nuwellis
Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company provides Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure, as well as Aquadex SmartFlow system for temporary use in adult and pediatric patients. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
NUWE Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple positive operational and strategic developments (notably 26% revenue growth, a 70.1% gross margin, pediatric adoption, the RendiaTech acquisition, a new patent, leadership and board strengthening, and a ~$5M capital infusion). However, notable challenges remain: a ~$4.3M net loss, operating expenses up ~46%, modest cash on hand (~$2.2M), and a multi-quarter timeline to commercialize RendiaTech's target product. On balance, the highlights indicate meaningful early execution progress and strategic positioning, but the company must deliver on its burn reduction and commercialization milestones to sustain momentum.View all NUWE earnings summariesNUWE Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Aethlon Medical
―
PAVmed
―
Catheter Precision
―
Bone Biologics
―
Heart Test Laboratories, Inc.
―
Ownership Overview
<0.01% Insiders
3.69% Mutual Funds
― Other Institutional Investors
96.31% Public Companies and
Individual Investors